Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,284 INR | -1.41% | -3.69% | +9.60% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.46 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.60% | 348.98Cr | C+ | ||
+20.39% | 4.37TCr | B- | ||
+26.21% | 2.28TCr | B+ | ||
+21.43% | 1.55TCr | - | ||
+18.82% | 1.43TCr | B+ | ||
+53.37% | 1.28TCr | B | ||
-0.05% | 678.76Cr | - | - | |
-11.88% | 651.62Cr | B+ | ||
-8.87% | 572.55Cr | - | - | |
+12.62% | 558.78Cr | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AJANTPHARM Stock
- Ratings Ajanta Pharma Limited